Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223333 · ClinicalTrials.gov registry record · Phase 1
A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers
A Phase 1 study of Type 2 Diabetes, sponsored by AdipoPharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 2
- Study locations
NCT07223333: Recruiting Phase 1 study of Type 2 Diabetes, sponsored by AdipoPharma.
NCT07223333 is a Phase 1 study of Type 2 Diabetes that is actively recruiting participants, run by AdipoPharma. The registered enrollment target is 56 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223333, a Phase 1 study of Type 2 Diabetes, is actively recruiting participants, sponsored by AdipoPharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects.
Primary Outcome
Incidence and severity (using CTCAE version 5.0.) of treatment-emergent AEs and SAEs and evaluation of pharmacokinetic data
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PATAS Trifluoroacetate
Study Locations (2)
Ohio
- Medpace Clinical Pharmacology Unit - Cincinnati
- Medpace Clinical Pharmaology Unit - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
What NCT07223333 shows while recruiting
NCT07223333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07223333 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07223333 about?
NCT07223333 is a clinical study titled "A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers". The primary objective of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects.
What is the current status of trial NCT07223333?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2026-01-27. Estimated completion is 2026-09-30.
What conditions does trial NCT07223333 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT07223333?
The interventions under investigation include: Placebo (DRUG), PATAS Trifluoroacetate (DRUG).
Who is sponsoring clinical trial NCT07223333?
This trial is sponsored by AdipoPharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223333 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07223333's enrollment target sits among peer trials
56 206th of 327 higher than 122 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
SGLT2i, Pioglitazone, and Ketone Production in T2D
RECRUITING · Phase 1
-
THC Effects on Glucose in Type 2 Diabetes
RECRUITING · Phase 1
-
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
RECRUITING · Phase 1
-
Polypill for Prevention of Cardiomyopathy
RECRUITING · Phase 1
-
SGLTi, Hepatic Glucose Production and Ketogenesis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI